The European Medicines Agency has published for public consultation a reflection paper on criteria to be considered for the evaluation of new active substance (NAS) status of biological substances.
This document describes the current scientific thinking applied to New Active Substance (NAS) assessment of biological active substances and provides guidance on the elements required to be submitted by applicants to substantiate a NAS claim. Advanced Therapy Medicinal Products (ATMPs) are within the scope of this document.
The different considerations that apply to the NAS assessment of active substances in this class of products are presented separately. Chemical active substances and radiopharmaceutical medicinal products are excluded from the scope of this reflection paper.
Comments should be provided using a template available on the EMA website and sent to BWPsecretariat@ema.europa.eu by 31 May 2023.
The EMA may collect and further process some personal data of stakeholders and interested parties who submit contributions to the consultations.
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
